http://purl.org/np/RAtSt1AfhV... RAtSt1AfhV

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#type type

http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement Statement

0000-0002-7641-6446

2021-08-25T14:52:33.344Z

http://purl.org/np/RAtSt1AfhV... RAtSt1AfhV

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/2000/01/rdf-schema#label label

Escitalopram showed favorable pharmacokinetics and good tolerability. It is the most 5-HT-selective among SSRIs, with little or no affinity for other transmitter transporters or receptors [59]. Compared to other SSRIs, escitalopram may have weak or minimal interactions with the cytochrome P450 system [60, 61]. In a randomized, double-blind, placebo-controlled 24-week trial in OCD, escitalopram (20 mg/day) was associated with an increase in response rate compared to placebo after 12 weeks. Other placebo-controlled studies consistently showed escitalopram-related treatment response [25, 30]. 20 mg/day escitalopram has also been associated with better OCD symptom remission compared to 40 mg/day paroxetine or placebo at week 12 [30]. Three different escitalopram dosages (5, 10, and 20 mg/day) were compared with a fixed, 20 mg/day dose of paroxetine in a 12-week study, in which escitalopram showed both greater efficacy and better tolerability [62].

0000-0002-7641-6446

2021-08-25T14:52:33.344Z

http://purl.org/np/RAtSt1AfhV... RAtSt1AfhV

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#object object

http://purl.obolibrary.org/obo/MONDO_0008114 MONDO_0008114

0000-0002-7641-6446

2021-08-25T14:52:33.344Z

http://purl.org/np/RAtSt1AfhV... RAtSt1AfhV

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate predicate

https://w3id.org/biolink/vocab/treats treats

0000-0002-7641-6446

2021-08-25T14:52:33.344Z

http://purl.org/np/RAtSt1AfhV... RAtSt1AfhV

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#subject subject

https://identifiers.org/DRUGBANK:DB01175 DRUGBANK:DB01175

0000-0002-7641-6446

2021-08-25T14:52:33.344Z

http://purl.org/np/RAtSt1AfhV... RAtSt1AfhV

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/has_population_context has_population_context

http://purl.org/np/RAtSt1AfhV...#context context

0000-0002-7641-6446

2021-08-25T14:52:33.344Z

http://purl.org/np/RAtSt1AfhV... RAtSt1AfhV

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/publications publications

https://pubmed.ncbi.nlm.nih.gov/30101713 pubmed.ncbi.nlm.nih.gov/30101713

0000-0002-7641-6446

2021-08-25T14:52:33.344Z

http://purl.org/np/RAtSt1AfhV... RAtSt1AfhV

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/provided_by provided_by

https://w3id.org/um/NeuroDKG NeuroDKG

0000-0002-7641-6446

2021-08-25T14:52:33.344Z

http://purl.org/np/RAtSt1AfhV... RAtSt1AfhV

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/relation relation

https://w3id.org/um/neurodkg/OffLabelIndication OffLabelIndication

0000-0002-7641-6446

2021-08-25T14:52:33.344Z